Business Wire

Gramercy Funds Management Announces Close of Gramercy Capital Solutions Fund III

18.11.2024 15:00:00 CET | Business Wire | Press Release

Share

Gramercy Funds Management LLC (“Gramercy”) a $6 billion global emerging markets investment manager, today announced the final close of its Gramercy Capital Solutions Fund III (“GCSF III” or the “Fund”), with $685 million in limited partner commitments to the Fund and an additional $75 million in co-investments to date. This combined raise of $760 million in the strategy represents a 28% increase from the June 2022 closing of the firm’s second fund (GCSF II) which closed with $592 million. The inaugural fund (GCSF I) closed in 2017 with commitments of $312 million. Virtually all the limited partners from GCSF I and GCSF II committed capital to GCSF III.

The Capital Solutions strategy is anchored by a dedicated 12-member team that has been working together for more than seven years. The team, led by Gustavo Ferraro as Senior Portfolio Manager, averages more than 20 years of experience in the field. The senior team is composed of Javier Ledesma-Arocena, Portfolio Manager, as well as Gian Marco Maltoni, Tomas Serantes, Lisandro Muller and Felipe Alonso. Headquartered in Greenwich, CT, the team is located throughout our investment region with offices in Argentina, Mexico and Miami, and is supported by our lending platforms located in Brazil, Colombia, Peru, Mexico and Turkey.

The Fund invests in USD loans, mostly primary, across Latin America (~75%) and CEEMEA (~25%), with a highly diversified approach across industries, company types and sizes. Loans aim to deliver attractive mid-teens returns with robust downside protection. They are typically structured as highly covenanted, asset-backed, self-liquidating structures, with strong LTV ratios and cash flow control. The Capital Solutions Investment Committee underwriting focuses on downside protection to our investment thesis and collateral value. Asymmetric risk-return is sought from managed cash-flow and asset-based collateral packages, structured for enforcement utilizing the best available and proven structures within EM jurisdictions.

Limited partners in the Fund consist of both existing and new investors located in Europe, North America and South America, including insurance companies, public pension plans, investment managers and family offices.

Gustavo Ferraro said, “We are excited to announce the final close of GCSF III and thank our investors for their commitment to this strategy. We believe our proven multi-channel approach to sourcing including our unique lending platforms providing strong visibility and rapid, dependable capital deployment remains very attractive to investors.” Regarding the investment environment he further commented, “…we have an ability to access a multitude of borrowers and negotiate attractive terms for the Fund because they see our capital as transformational for their businesses and growth aspirations.”

“Gramercy’s differentiated, better approach to emerging markets continues to prove effective through market cycles, and we look forward to deploying this new capital,” said Robert Koenigsberger, Managing Partner and Chief Investment Officer of Gramercy. He added, “Gramercy is a longstanding leader in emerging markets with over 25 years of expertise and an extensive global footprint. We leverage the depth of experience and knowledge represented in our investment team to focus on the best opportunities in private credit and direct lending corporate markets.”

To date, Gramercy has deployed approximately $5 billion in capital in this strategy across over 100 investments. The firm is optimistic regarding the opportunity to deliver for their investors through 2025 and beyond.

About Gramercy Funds Management

Gramercy is a global emerging markets investment manager based in Greenwich, Connecticut with offices in London, Buenos Aires, Miami, West Palm Beach and Mexico City, and dedicated lending platforms in Mexico, Turkey, Peru, Pan-Africa, Brazil, and Colombia. The $6-plus billion firm, founded in 1998, seeks to provide investors with a better approach to emerging markets, delivering attractive risk-adjusted returns supported by a transparent and robust institutional platform. Gramercy offers alternative and long-only strategies across emerging markets asset classes, including multi-asset, private credit, public credit, and special situations. Gramercy’s mission is to positively impact the well-being of our clients, portfolio investments and team members. Gramercy is a Registered Investment Adviser with the US Securities and Exchange Commission (SEC), a Signatory of the Principles for Responsible Investment (PRI), a Signatory to the Net Zero Asset Managers initiative (NZAMI) and a Supporter of the Task Force on Climate-Related Financial Disclosures (TCFD). Gramercy Ltd, an affiliate, is registered with the UK Financial Conduct Authority (FCA). For more information, visit www.gramercy.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241118827551/en/

Contacts

Media Contacts

Steve Bruce / Keely Gispan
ASC Advisors
(203) 992-1320
sbruce@ascadvisors.com / kgispan@ascadvisors.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press Release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye